Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic...

Full description

Bibliographic Details
Main Authors: Giovanni Battista Migliori, Emanuele Pontali, Giovanni Sotgiu, Rosella Centis, Lia D’Ambrosio, Simon Tiberi, Marina Tadolini, Susanna Esposito
Format: Article
Language:English
Published: MDPI AG 2017-02-01
Series:International Journal of Molecular Sciences
Subjects:
MDR-TB
XDR-TB
delamanid
bedaquiline
effectiveness
safety
tolerability
Online Access:http://www.mdpi.com/1422-0067/18/2/341

Internet

http://www.mdpi.com/1422-0067/18/2/341

Similar Items